Objectives: Bevacizumab (Avastin) and chemotherapy delivered through an intraperitoneal regimen can be highly effective, but also highly toxic. The primary outcomes of this study measure progression-free survival, but investigators will also be looking at death rates and severity of adverse events.
Key Entry or Exclusion Criteria: Patients with mucinous, low-grade, or clear cell disease are eligible unless there is a higher-priority Gynecologic Oncology Group trial open. Participants must have undergone surgery for diagnosis, staging, and/or cytoreduction within the past 12 weeks.
Locations: 443 sites.
Goal: 1,500 patients.
Study sponsor: Gynecologic Oncology Group in collaboration with the National Cancer Institute.
Link for more information: clinicaltrials.gov/ct2/show/NCT00951496
NIH clinical trials identifier: NCT00951496